Aberdeen Asset Management, which is hoping to get the investment manager gig at Alliance Trust should the under-siege investment trust outsource its portfolio management, was the top performing blue-chip on Tuesday after Morgan Stanley recommended acquiring the shares. Drugs giant GlaxoSmithKline was another riser, although not enough to make the top 10, having received top-line results from seven of the eight 'Harmony' drug development Phase III studies investigating the use of albiglutide in type 2 diabetes. Glaxo said that based on the studies it has performed so far, there is enough information to support progression to regulatory submissions, as a possible once-weekly treatment for type 2 diabetes. Meanwhile, contract caterer Compass became a big faller after Morgan Stanley cut its rating from 'overweight' to 'equal weight', though the price target has been raised from 630p to 670p. Blackrock, a major holder of the stock, lobbed out 8.3m shares of the stock following the downgrade. FTSE 100 - RisersAberdeen Asset Management (ADN) 270.50p +4.40%Burberry Group (BRBY) 1,561.00p +2.16%ICAP (IAP) 397.30p +1.15%Admiral Group (ADM) 1,202.00p +1.09%Glencore International (GLEN) 403.50p +1.09%IMI (IMI) 1,005.00p +1.01%BG Group (BG.) 1,490.00p +0.78%Ashmore Group (ASHM) 376.10p +0.64%Next (NXT) 3,060.00p +0.62%Xstrata (XTA) 1,103.50p +0.59%FTSE 100 - FallersRoyal Bank of Scotland Group (RBS) 26.69p -3.82%Pearson (PSON) 1,186.00p -2.87%Man Group (EMG) 130.40p -2.18%Randgold Resources Ltd. (RRS) 5,320.00p -1.85%Lloyds Banking Group (LLOY) 32.97p -1.83%Compass Group (CPG) 659.00p -1.79%Vedanta Resources (VED) 1,238.00p -1.75%CRH (CRH) 1,277.00p -1.69%Old Mutual (OML) 160.10p -1.66%Resolution Ltd. (RSL) 259.20p -1.63%NR